Aktien Sensor

Quest Diagnostics has introduced AD-Detect, a blood test that boasts over 90% accuracy in diagnosing Alzheimer’s disease, potentially revolutionizing the way the condition is diagnosed and managed.

Quest Diagnostics has launched a new FDA-cleared HPV self-collection solution, but experts warn that it may not be enough to address the alarming decline in cervical cancer screening rates in the US.

Quest Diagnostics is set to release its Q1 2025 earnings on April 22, 2025, with investors anticipating the company’s continued growth and innovation in the healthcare industry.

Quest Diagnostics’ stock performance has drawn attention from investors and analysts, with its current price of $167.33 USD and valuation metrics sparking interest in its future trajectory.

Quest Diagnostics’ stock price has been volatile, with a 52-week high of $178.87 and a 52-week low of $125.42, leaving investors wondering what’s next for the company.

Quest Diagnostics partners with Google Cloud, while NVIDIA introduces new AI solutions, potentially boosting stock performance for companies involved in the partnerships.

Quest Diagnostics reaffirms its 2025 guidance, projecting steady revenue and earnings growth, with a long-term outlook of 4-5% revenue and 7-9% EPS growth beyond 2025.

Quest Diagnostics’ stock has experienced fluctuations, with a current closing price of $170.16 USD and a 52-week range of $125.42 to $178.87 USD.

Quest Diagnostics’ stock has experienced fluctuations, with a current price of $170.16 USD, and requires further analysis to understand its performance.

Quest Diagnostics’ stock has seen significant fluctuations, with its price closing at $173.46 USD, prompting investors and analysts to examine its valuation metrics and future prospects.